These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 8094803)
1. Ondansetron for hallucinosis in advanced Parkinson's disease. Zoldan J; Friedberg G; Goldberg-Stern H; Melamed E Lancet; 1993 Feb; 341(8844):562-3. PubMed ID: 8094803 [No Abstract] [Full Text] [Related]
2. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Zoldan J; Friedberg G; Weizman A; Melamed E Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178 [No Abstract] [Full Text] [Related]
3. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. Graham JM; Sussman JD; Ford KS; Sagar HJ J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):774-7. PubMed ID: 9810956 [TBL] [Abstract][Full Text] [Related]
4. A possible case of peduncular hallucinosis in a patient with Parkinson's disease successfully treated with quetiapine. Spiegel DR; Lybeck B; Angeles V J Neuropsychiatry Clin Neurosci; 2009; 21(2):225-6. PubMed ID: 19622697 [No Abstract] [Full Text] [Related]
5. Treatment of organic hallucinosis with carbamazepine. Stewart JT; Yelton JA Am J Psychiatry; 1995 Jan; 152(1):150. PubMed ID: 7802109 [No Abstract] [Full Text] [Related]
6. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Zoldan J; Friedberg G; Livneh M; Melamed E Neurology; 1995 Jul; 45(7):1305-8. PubMed ID: 7617188 [TBL] [Abstract][Full Text] [Related]
11. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. van Laar T; Postma AG; Drent M Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477 [No Abstract] [Full Text] [Related]
12. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey]. Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R; Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176 [TBL] [Abstract][Full Text] [Related]
13. Case history of a patient with musical hallucinations and Parkinson's disease. Clark J Int J Geriatr Psychiatry; 1998 Dec; 13(12):886-7. PubMed ID: 9884914 [No Abstract] [Full Text] [Related]
14. Behavioral indicators of hallucinosis in levodopa-treated Parkinson's disease. Glantz RH; Bieliauskas L; Paleologos N Adv Neurol; 1987; 45():417-20. PubMed ID: 3825719 [No Abstract] [Full Text] [Related]
15. [Management of psychiatric complications of Parkinson's disease]. Fénelon G Rev Prat; 2005 Apr; 55(7):733-9. PubMed ID: 15966416 [TBL] [Abstract][Full Text] [Related]
16. Cenesthetic hallucinations in a patient with Parkinson's disease. Jiménez-Jiménez FJ; Ortí-Pareja M; Gasalla T; Tallón-Barranco A; Cabrera-Valdivia F; Fernández-Lliria A J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):120. PubMed ID: 9221983 [No Abstract] [Full Text] [Related]
18. Management of hallucinations and psychosis in Parkinson's disease. Eng ML; Welty TE Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621 [TBL] [Abstract][Full Text] [Related]
19. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968 [TBL] [Abstract][Full Text] [Related]